Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.
Unicycive Therapeutics has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
Unicycive Therapeutics's investors include RA Capital Management, Vivo Capital, Great Point Partners, Walleye Capital, Octagon Capital Advisors.
Unicycive Therapeutics is headquartered in Los Altos, United States.
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.
Unicycive Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Unicycive Therapeutics — Funding & Investors." VCBacked, March 14, 2024, https://www.vcbacked.co/company/unicycive-therapeutics. Accessed November 12, 2026.
VCBacked. (2024). Unicycive Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/unicycive-therapeutics
{{cite web |title=Unicycive Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/unicycive-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Unicycive Therapeutics? Request a listing update